Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Dr. Vogel on the FIGHT-202 Trial in Cholangiocarcinoma

September 28th 2019

Arndt Vogel, MD, PhD, professor of gastrointestinal oncology, Hannover Medical School, discusses the results of the open-label, single-arm phase II FIGHT-202 trial in cholangiocarcinoma.

Atezolizumab Plus Bevacizumab Impresses in Unresectable HCC

September 28th 2019

Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.

TAS-102 Becomes Promising Option in Chemorefractory Gastric/GEJ Cancers

September 27th 2019

David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.

POLO Trial Underscores Need for Screening in Metastatic Pancreatic Cancer

September 27th 2019

Donald A. Richards, MD, PhD, highlights the key takeaways from the pivotal POLO trial and underscores the importance of genetic testing in metastatic pancreatic cancer.

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic Cancer

September 27th 2019

Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.

Dr. Messersmith on Choosing a Treatment Option in mCRC

September 26th 2019

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC

September 25th 2019

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Dr. Mehta on Recent Progress Made in Advanced Gastric Cancer

September 24th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses recent progress that has been made in advanced gastric cancer.

Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic Cancer

September 23rd 2019

Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.

FDA Approves CRC Screening Test for Younger, At-Risk Individuals

September 23rd 2019

The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

September 21st 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.

Experts Dissect Key Findings for Progressive Gastric and GEJ Cancers

September 20th 2019

Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.

Top GI Oncologists Share Excitement on 16th Annual ISGIO Conference

September 20th 2019

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.